Skip to main content

Table 2 EGFR exon 19 deletions/substitution

From: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

# Sex Ethnicity Smoking Status Source Tissue Response1 I    K    E    L    R    E    A    T    S    P    K a.a.
       T C A A G G A A T T A A G A G A A G C A A C A T C T C C G A A CDS
11 F Asian Unk. Lung PR T C A A - - - - - - - - - - - - - - - A A C A T C T C C G A A Het*
22 M Asian N Lymph Node PD T C A A G G A A - - - - - C - - - - - - - C A T C T C C G A A Het
25 F Asian N Lung PD T C A A G G A A - - - - - - - - - - - - - - - T C T C C G A A Del
66 F Asian N Lung PR T C A A - - - - - - - - - - - - - - - A A C A T C T C C G A A Het*
  1. Deletions of L747-A750 were detected in EGFR exon 19. All samples were classified as adenocarcinoma based on histology. Deleted bases are indicated by "-". In the case of patient #22, thirteen deleted bases were replaced by a single 'C' thereby retaining the reading frame. In all cases, the ATP-binding residue K745 was retained. In the case of patients #11 and #66, a synonymous codon change results from the deletion (AAG > AAA) and the K745 ATP-binding residue is unchanged.
  2. * = no mutations detected in normal tissue remaining after microdissection.
  3. 1 = response as measured radiographically and defined by SWOG modification of the WHO criteria.
  4. PD = progressive disease, SD = stable disease, PR = partial response, Unk. = Unknown